Search

Objectives: The aim of this study was to assess the impact of the aggressiveness of cancer cells at the level of positive surgical margins (PSM) on the biochemical recurrence rate (BRR) by studying the Gleason score (GS) at this level., Methods: We included all radical prostatectomy (RP) procedures performed from January 2007 to November 2011. All of the RP specimens with PSM were reviewed to determine the GS at the level of PSM. We compared the GS at PSM with BRR., Results: A total of 658 RP were analysed, among which 16% had PSM. From the 101 patients with PSM included, 32% had biochemical recurrence (BR) with a median follow-up of 38 months. GS at PSM was significantly associated with earlier BR (P=0.008). Univariate analysis showed that GS at PSM (P=0.013), initial PSA (P<0.0001), pathologic GS (P<0.001), length of PSM (P=0.013), and seminal vesicle invasion (P<0.0001) were predictors of BR. Multivariate analysis confirmed that PSA greater than 10ng/mL and length of PSM greater than 3mm were independent prognostic factors for BR, but GS at the level of PSM was not., Conclusion: GS at PSM was not confirmed as an independent risk factor for BR. Initial PSA greater than 10ng/mL and length of PSM greater than 3mm were the sole independent predictors for BR., Level of Proof: 4., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)

Objectives: To assess the postoperative functional outcome of PN in solitary kidney and define some predictive factors of renal change., Material and Methods: A monocentric series of 45 partial nephrectomies on solitary kidneys, performed between 1988 and 2014, was retrospectively analyzed. Pre-, per- and postoperative clinicopathological data were collected in the UroCCR database. The evolution of early, medium and long-term postoperative Glomerular Filtration Rate (GFR) was evaluated. Predictive factors of GFR decline and hemodialysis were assessed in multivariate analysis., Results: Mean age was 61 years old (±10.8). Mean preoperative GFR and tumor size were respectively 59.6 mL/min (±18.7) and 3.9 cm (±2.6). Vascular clamping was performed in 41 cases (91%). Median time of warm ischemia was 20 minutes (2-60). Mean follow-up was 66 months (±47). Mean GFR at day 5, 1 month and last follow-up were respectively 46.4 mL/min, 50.3 mL/min and 53.1 mL/min. At day 5 and at last follow-up, a GFR decrease ≥ 20% was found in 20 patients (44.4%) and in 16 patients (35.5%), respectively. Five patients (11%) required definitive hemodialysis (HD) at last follow-up. At day 5, tumor size>4 cm (0.006) and operative time (P=0.003) were independent predictive factors of GFR decline. At 1 year, RENAL ns ≥ 10 was the only independent predictive factor of GFR alteration (P=0.0007). Preoperative GFR was significantly associated with final hemodialysis (P=0.023)., Conclusion: Partial nephrectomy allows most of the patients presenting with renal cell carcinoma on solitary kidney to be free of hemodialysis. Tumor complexity, tumor size and preoperative GFR seems to play a determinant role on postoperative functional outcome. These non-modifiable predictive factors should be recognized and taken into account to better select patients with high risk of postoperative renal failure., Level of Evidence: 5., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)

Objective: To study the oncologic and functional results of HIFU as a first-line treatment for localized prostate cancer., Material and Method: Enrolment of patients between 2006 and 2011 for the first treatment against localized prostate cancer with HIFU (Integrated Imaging(®), EDAP-TMS, Vaulx-en-Velin, France). The biochemical recurrence-free survival was calculated by using the Phoenix criterion (PSA>nadir+2 ng/mL). The functional complications were assessed clinically and through standardised questionnaires., Results: The condition of 191 patients was assessed at a mean follow-up of 55.5 ± 22.7 months. In 10,1% of the treatments, an incident during the medical procedure was observed with the volume of the prostate (P=0.026) as risk factor. The overall survival, the survival and the metastatic free survival rate were respectively 89.5%, 98.4% and 97.4%. The biochemical free survival rate for 5 years was 87.5%, 69% and 39% respectively for the low, medium and high-risk groups of d'Amico classification. Eighty-six percent of the patients with a PSA nadir ≤ 0.3 ng/mL were relapse free at 5 years. Whereas only 48% of the patients with a nadir>0.3 ng/mL did not. Only 17.8% of the patients had a rescue treatment with an average delay of 31.1 months. The urinary and sexual impairment was significant but 78.1% of the patients were dry at the end of the study. The most common complication found in 18.3% of the patients was the prostatic obstruction., Conclusion: The oncologic and functional results of the HIFU seem similar to the other first-line treatments results and reveal that the HIFU is a therapeutic option for the treatment of prostate cancer in men over 70 years., Level of Evidence: 5., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)

Objective: To describe the prevalence and time of occurrence of vaginal mesh exposure based on the initial surgical approach of prolaps. To describe their therapeutic management., Material: Descriptive retrospective study of 43 women followed for vaginal mesh exposure diagnosed during a follow-up visit or motivated by symptoms. The initial surgery was performed abdominally (promontofixation) or vaginally. The therapeutic management was carried out by medical and/or surgical (prosthetic resection partial or complete)., Results: The prevalence of vaginal exposure was 7.3% in case of vaginal initial surgery and 2.8% in case of promontofixation initial (P=0.02). Mesh exposure have appeared earlier in case of vaginal initial surgery compared to promontofixation (14.9 months vs. 45.2 months). After vaginal initial surgery, vaginal mesh exposure appeared to third within 6 months postoperatively (9/29). The success rate of medical treatment was 21.4%. In total, 31% of women initially made vaginally and 64.9% of women initially made abdominally required at least two surgeries to get a cure., Conclusion: Vaginal mesh exposure may be away from the initial surgery, especially when the first initial surgery was abdominal. The medical treatment of vaginal mesh exposure led to poor results. The overall rate of healing in our experience was good but at the cost of considerable morbidity as a significant proportion of patients required two or more surgical interventions., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)

Aim: Systematically review literature on the efficacy and tolerability of botulinum toxin A (onabotulinumtoxineA, BOTOX(®), Allergan, CA, USA) in refractory idiopathic overactive bladder (iOAB) METHODS: Pubmed search on the efficacy, toxicity and adverse events of onabotulinumtoxinA in clinical trials only with level 1 and 2 evidence., Results: Eleven controlled randomised trials have been selected, of which 3 phase III trials. The studies published data of 1008 patients with refractory iOAB treated with onabotulinumtoxineA. In the phase II and III trials, doses from 50 U to 300 U have been evaluated; more than half of the patients (n = 676) with 100 U. In the 2 main phase III trials, onabotulinumtoxinA has demonstrated to be more efficient compared to placebo on continence, symptoms and quality of live (QoL). Urodynamic results, reported in the phase II trials, demonstrated higher changes compared to placebo only from dose 100 U on, although not always significant. Adverse events (urinary retention, dysuria, urinary tract infection) were easily treated and did not influence patient's QoL., Conclusion: Intradetrusor injections of onabotulinumtoxinA (BOTOX(®)), a minimally-invasive procedure, seem to be efficient and well tolerated in the treatment of refractory iOAB., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)

Objectives: To estimate in the medium term, the efficiency and morbidity of Advance(®) for the treatment of postoperative urinary incontinence for male, and determine predictive preoperative factors of success or failure., Material and Methods: Retrospective multicentric clinical study of patients presenting a postoperative urinary incontinence and treated by Advance(®) suburethral sling. The importance of the preoperative incontinence was classified in three groups: light (pad-test<50 g/day or 1 pad/day), moderated (pad-test between 50 and 100 g/day or 2 or 3 pads/day), severe (pad-test>100 g/day or >3 pads/day). The functional results were classified in 4 categories: continence and improvement, defining the criterion of success and unchanged situation and deteriorated situation defining the criterion of failure., Results: Sixty-six patients were included from 2008 till 2013. The radical prostatectomy was responsible in 85.5% of the cases. The incontinence was light, moderated and severe for respectively 43.4%, 35.6% and 21% of the patients. After treatment, 39.4% of the patients were continent and 78.9% in situation of success. The rate of success decreased with the severity of the incontinence (respectively 94%, 74% and 56%). For 9 patients, implantation of artificial urinary sphincter was performed without operative difficulties. Complications were urine retention (n=4), hematoma (n=3) and scrotal pains persistent more than one postoperative month (n=11)., Conclusion: Advance(®) suburethral sling is a technique in which the efficiency decreases with the severity of the incontinence, but which does not seem to prevent from implanting artificial urinary sphincter. Its main problem is the apparition of scrotal pain., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)

Objectives: To evaluate the feasibility of holmium laser enucleation of the prostate (HoLEP) as a day case surgery., Material and Methods: Observational prospective study including 30 consecutive patients after exclusion of unstable diseases and anticoagulant therapy. Patients were discharged before 8PM and the urinary catheter was removed at home the next morning. The monitoring included a phone call after 24hours and clinical evaluations after 1 and 3month follow-up. Clinical data were prospectively collected and complications were classified according to the Clavien-Dindo classification., Results: The mean age of the study population was 63.8, prostate volume was 75.3cc, maximum urinary flow rate was 9.5mL/s, and IPSS was 22.9. The conversion rate to conventional hospitalization was 3.3%. After 3months follow-up, readmission and reoperation rates were respectively 16.6% and 3.3%. The overall complication rate was 66% (Clavien I=57.7%, II=38.5%, III=3.8%). The satisfaction rate was 100% (score=9.2/10). The mean prostate volume at 3months follow-up was 23.3cc, maximum urinary flow was 25.6mL/s, and IPSS was 4.7., Conclusion: This study confirmed the feasibility of HoLEP as a day case surgery for selected patients. Conversion rate to conventional hospitalization and complications of grade >2 were less than 5% while the satisfaction rate was high., Level of Evidence: 3., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)

Introduction: Sacral nerve stimulation (NMS) is a therapeutic alternative for the treatment of urinary functional disorders as diverse as overactive bladder (OAB), urinary retention or pelvic pain syndromes. With the increasing use of NMS, we must deal with the postoperative management of this therapy., Objective: We report the results, postoperative adverse events and their management in our center., Patients: This is a retrospective single-center single-operator study of 93 patients who were tested for NMS between January 2005 and December 2013., Results: Of the 93 patients, 78 had a definitive implantation of the device for OAB (n=44), urinary retention (n=11), pain, interstitial cystitis (n=12), bladder hyperactivity and pain (n=8) or dysuria (n=3). The average follow-up was 38.86 months (2.06 to 88.3±28.9). Among patients with OAB, 75% had a clinical improvement greater than or equal to 50%, 11.3% were considered as cured. Among patients with urinary retention, 63.5% were improved. Painful patients were improved for 58.3% of them, 2 were considered as cured. We reported 3 early postoperative complications (2 local infections, 1 hematoma), and adverse events in 49 patients (multiple visits for parameter settings, revision of the device [n=38], explantation [n=14])., Conclusion: Our results confirm the long-term effectiveness of NMS for the treatment of refractory overactive bladder, urinary retention, chronic pelvic pain, vesico-uretral dyssynergies. Studies are still needed to improve the selection of ideal candidates, identify prognostic factors and reduce the rate of complications and revisions., Level of Evidence: 4., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)

Objective: Provide guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic overactive bladder management., Patients and Methods: Guidelines using formalized consensus guidelines method. These guidelines have been validated by a group of 13 experts quoting proposals, subsequently reviewed by an independent group of experts., Results: In the case of patients with urinary tract infection, it must be treated and injection postponed. Before proposing an injection, it is recommended to ensure the feasibility and acceptability of self-catheterisation by patient. The injection can be performed after local anesthesia of the bladder and urethra (lidocaine), supplemented where necessary by nitrous oxide inhalation and sometimes under general anesthesia. Injection is performed in the operating room or endoscopy suite. The bladder should not be too filled (increased risk of perforation). Treatment should be applied in 10 to 20 injections of 0.5 to 1 mL homogeneously distributed in the bladder at a distance from the urethral orifices. It is not recommended to leave a urinary catheter in place except in cases of severe hematuria. The patient should be monitored until resumption of micturition. After the first injection, an appointment must be scheduled within 3 months (micturition diary, uroflowmetry, measurement of residual urine and urine culture). Performance of self-catheterisation should be questioned in the case of a symptomatic post-void residual and/or a residue>200 mL. A new injection may be considered when the clinical benefit of the previous injection diminishes (between 6 and 9 months). A period of three months must elapse between each injection., Conclusions: Implementation of these guidelines may promote best practice usage of BoNTA with optimal risk/benefit ratio., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)

Objectives: Provide guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic Overactive Bladder management., Patients and Methods: Guidelines using formalized consensus guidelines method. These guidelines have been validated by a group of 13 experts quoting proposals, subsequently reviewed by an independent group of experts., Results: In the case of patients with urinary tract infection, it must be treated and injection postponed. Before proposing an injection, it is recommended to ensure the feasibility and acceptability of self-catheterisation by patient. The injection can be performed after local anesthesia of the bladder and urethra (lidocaine), supplemented where necessary by nitrous oxide inhalation and sometimes under general anesthesia. Injection is performed in the operating room or endoscopy suite. The bladder should not be too filled (increased risk of perforation). Treatment should be applied in 10 to 20 injections of 0.5 to 1mL homogeneously distributed in the bladder at a distance from the urethral orifices. It is not recommended to leave a urinary catheter in place except in cases of severe hematuria. The patient should be monitored until resumption of micturition. After the first injection, an appointment must be scheduled within 3 months (micturition diary, uroflowmetry, measurement of residual urine and urine culture). Performance of self-catheterisation should be questioned in the case of a symptomatic post-void residual and/or a residue>200mL. A new injection may be considered when the clinical benefit of the previous injection diminishes (between 6 and 9 months). A period of three months must elapse between each injection., Conclusions: Implementation of these guidelines may promote best practice usage of BoNTA with optimal risk/benefit ratio., (Copyright © 2013 Elsevier Masson SAS. All rights reserved.)

Objectives: Assessment of the adjustable continence therapy device (ACT) in the treatment of female stress or mixed urinary incontinence in terms of efficacy and complications., Material: Between April 2005 and September 2011, the device ACT was put by two different operators to treat a stress and/or mixed urinary incontinence at women. The results were studied under two shutters: complications and efficacy., Results: Seventy-seven women were operated. Mean age of the patients was of 68 years (34-87). Mean follow-up was of 22 months (1-72). Over the 77 patients, eight peroperative complications (10%) were noted. Twenty-five explantations were required in 22 patients (28%). In terms of efficacy, after an average follow-up of 22 months, the results were: 19 patients (25%) were continents, 25 (33%) very improved and five (6%) improved regards to the initial stage preceding the implantation. Fifteen patients (19%) were in failure. Seven patients (9%) were unchanged and in the course of adjustment (recent implantation) and six others (8%) explanted waiting for another implantation., Conclusion: The ACT procedure was feasible on a population of multi-operated women with 64% of improvement in our hands. Complications were rare, easily detected and repaired. The risk of explantation was reported to be 28%., (Copyright © 2013. Published by Elsevier Masson SAS.)

Objective: To assess the effectiveness and tolerance of the metallic stent Memokath® 051 in the management of patients with chronic ureteral stricture treated by JJ stenting., Patients and Methods: A prospective observational study included 16 patients with chronic ureteral stricture managed with JJ stents. They were all treated with Memokath® 051 metallic stents. The primary endpoint was the medium durability of the stent. Adverse events and complications were prospectively collected. The evolution of the irritative urinary symptoms and lumbar pain after stent insertion were also assessed., Results: Sixteen patients (mean age: 62, standard deviation: 11,4) had a total of 20 stents inserted. It was technically impossible to insert the stent in two patients and one stent was removed one day after insertion. The medium durability of the stents was 13 months (standard deviation: 10,9). Eight stents (40%) were still functioning at the end of the study. Complications were: six migrations (30%) and four obstructions (20%) of the stents. Thirteen of the 14 patients with a Memokath® stent experienced significant improvement of their JJ stent-related symptoms., Conclusion: The Memokath® 051 stent was an interesting alternative to JJ stents in the management of chronic ureteral strictures. Their tolerance was good and complications were easily managed without threatening the urologic prognosis of the patients. Larger studies are required to identify the risk factors of complications and the best indications for stent insertion., (Copyright © 2012 Elsevier Masson SAS. All rights reserved.)

Ureteric herniations are extremely rare. We are reporting the case of a 57-year-old female presenting with an upper urinary tract sepsis due to a pelvic ureteral herniation into the supra-piriform sciatic foramen. The diagnosis was made by the CT scan and the treatment was performed in two steps: first the upper urinary tract was drained, and then the hernia was surgically treated. Although ureteral hernias are exceptional causes for nephritic colic, urologists must be aware of the specificity of the diagnosis and of the treatment in order to avoid complications., (Copyright © 2011 Elsevier Masson SAS. All rights reserved.)

Aim: To analyse current practice patterns and to evaluate (long-term) effectiveness and adverse events of sacral neuromodulation with InterStim™ Therapy based on data collected in a national register and to discuss the strengths and weaknesses of the register., Patients and Methods: This is a French multicenter prospective observational trial including patients with a permanent implant (2003-2009). Voiding diary variables and patient satisfaction were analysed based on last follow-up visit since implantation., Results: One thousand four hundred and eighteen patients (median age: 63 years, 1206 females) were included in the database (median follow-up: 12 months). One thousand and eighty-nine patients had non-neurological disease. The principal diagnosis was overactive bladder syndrome ([OAB], n=1170) and retention (n=151). Implantation occurred in 1358 patients; 1172 patients had greater than or equal to one registered follow-up. Clinical improvement of greater than or equal to 50% was seen in 447/527 patients with OAB at 12 months follow-up (median number of voids per 24 hours decreased from 15 at baseline to 8 at 12 months) and in 42/54 of patients with retention (median number of catheterization per 24 hours dropped from 5 at baseline to 0 at 12 months). Clinical improvement remained relatively stable up to 60 months. Median patient satisfaction with treatment was between 60 and 80%. Five hundred and twenty-four patients had at least one adverse event; loss of efficacy (n=244) occurred most frequently., Conclusions: In this large database sacral neuromodulation with InterStim™ Therapy seems to be an effective treatment through routine practice in the long-term (up to 60 months) for patients refractory to medical treatment., (Copyright © 2010 Elsevier Masson SAS. All rights reserved.)

Purpose: Compare, in a retrospective study, the indications, the efficiency and the morbidity of the flexible ureteroscopy (URS) and the mini percutaneous nephrolithotomy (mini-perc) for the treatment of the renal lithiasis less or equal to 2 cm., Materials and Methods: One hundred and forty-four operated patients: 101 by "mini-perc" and 43 by URS. Pre-, per- and post-operative data prospectively entered in a computerized database., Results: URS and "mini-perc" groups were comparable in terms of age (49.2±14 years versus 51.7±16 years; P=0.37) and of size of the lithiasis (8.5±3.2 mm versus 8.9±2.7 mm, P=0.4). However, the number of lithiasis was more important in URS group (2.7±141.6 versus 1.3±0.38; P<0.05). The operating time was 59±32.6 min in URS and 48±28.3 min "mini-perc" group (P=0.05). The peroperating complication rate was 2% for URS (a false passage during the introduction of the access girdle) and null in the "mini-perc" group. The hospitalization was 1.49±11.4 days after URS and of 4.1±1.2 days after "mini-perc" (P<0.05). The duration of ureter drainage by stent was respectively 13.8±11.5 and 2.6±1.2 days (P<0.05). One month later, the treatment was effective in 88% of cases in the URS group whereas 93% in "mini-perc" group (P=0.17). Six patients (14%) need complementary treatment for residual lithiasis in the URS group and four (3.9%) in the "mini-perc" group., Conclusion: The "mini-perc" and the URS are two effective techniques for the treatment of the renal lithiasies less or equal to 2 cm. For the two groups, the complication rates were low and the length of hospital stay was short., (Copyright © 2010 Elsevier Masson SAS. All rights reserved.)

Aims: Analyse changes in voiding patterns after the treatment of female urodynamic stress incontinence (USI) with suburethral transobturator tape (TOT)., Patients and Methods: Prospective study of 50 women with pure stress urinary incontinence treated between March 2004 and February 2006; mean age was 53+/-13 (34-87); parity was 2+/-0.75; mean follow-up was of 15 months (7-43). Each patient did a complete urodynamic examination and filled in two questionnaires (MHU and Contilife), before and three months after surgery., Results: Cure rate was 94% (47/50). Three of 50 patients remained incontinent after surgery (6%). No peroperative complications occurred. Analysis of questionnaires showed that two clinical symptoms predominated postoperatively: dysuria (14%; n=7) and urgency (6%; n=3). Urodynamic profiles showed the following: a decrease in maximum flow rate from 23.6 to 18.9 ml/s (p<0.01), and an increase in urethral resistance from 0.12 to 0.23 (p<0.01). The number of patients with at least two Massey Abrams criteria defining obstruction rose from six to 19, while only seven patients had symptomatic dysuria. Quality of life improved significantly, from 2.32 to 4.63 (p<0.05)., Conclusions: TOT is a safe, effective procedure with few complications. While urodynamic data show some obstruction, this has little impact upon clinical results or mid-term complications; it only mildly affects voiding and does not compromise patient satisfaction., (Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.)

The physiopathology of urinary incontinence in women is complex. It must be thoroughly understood to orient the therapeutic choices available to patients. In urge incontinence, the initial management is above all conservatory, based on medical treatments and rehabilitation. In stress urinary incontinence, the quality of the urethra guides the indications for support techniques, with suburethral slings taking the lead and a preference for the retropubic approach in cases of sphincter deficiency with mobility of the urethrovesical junction preserved. In mixed urinary incontinence, the choices are always difficult and generally one begins with treating the component that is the most uncomfortable for the patient. Whatever choice is made, one must be aware that the first treatment often influences future treatments., ((c) 2010 Elsevier Masson SAS. All rights reserved.)

The last two decades have brought about new medical and surgical treatments revolutionizing care for non-neurological urinary incontinence in women. Many studies, often randomized prospective studies with sufficient follow-up, have validated the therapeutic choices and shown them not to be part of a fad or marketing pressures. The French Association of Urology (L'Association Française d'Urologie), through its Committee on Women's Urology and Pelviperineology (Comité d'Urologie et de Pelvipérinéologie de la Femme), proposes its recommendations. These were established by an expert group of specialists (urologists, gynecologists, and physical therapists), based on a review of the literature but taking into account the daily practices in academic and private practice settings. Between evidence-based medicine and reality in the field, these recommendations attempt to propose realistic and applicable strategies., ((c) 2010 Elsevier Masson SAS. All rights reserved.)

Introduction: Total prostatectomy (TP) is one of the referential treatments of localized cancer of the prostate gland. Urethrovesical anastomosis and urinary catheterization may be sources of strong contractions of the detrusor muscle responsible for intense pain which is added to parietal pain. This study evaluates the efficiency of oxybutynin in the treatment of this postoperative pain (POP)., Material and Method: Forty-five patients due to benefit from a TP by laparotomy were included in this prospective study. A urinary catheter was put in place during the operation. Patients were randomly split into two groups in the postoperative care room. Group P (n = 23) received a placebo in tablet form and group O (n = 22) received 5mg of oxybutynin in sublingual form. The POP was evaluated every 2 hours using the Visual Analogue pain Scale (VAS 0:10)., Results: The accumulated dose of tramadol after 8 hours was 110.8 mg in group P and 39.7 mg in group O (p < 0.05). For group P, 15/23 of the patients (65%) were in pain versus 4/22 (18%) in group O. The VAS scores of group P were higher (4.1 +/- 1) than those of group O (1.2 +/- 0.9). For group P, when the PCA dose of tramadol was inefficient, a tablet of oxybutynin 5 mg brought the VAS scores down to the same level of those of group O within 2 hours. No side effects linked to the antimuscarinic action were observed., Conclusion: Oxybutynin given in sublingual form reduced, at postoperative stage, the frequency and intensity of pain linked to the bladder wound and to the catheter after TP. Its use for the POP of the bladder section reduced the consumption of postoperative analgesia.

Objective: To describe the management of patients with an erosive complication after tension free vaginal tape. To establish a diagnostic approach, describe the results on symptoms and continence after a conservative surgery., Methods: Retrospective descriptive study of 38 patients supported for complications after suburethral synthetic sling. We have diagnosed 12 erosions vaginal and five bladder erosions. Patients have been treated from a recovery surgery according to a conservative approach (partial resection or endoscopic section)., Results: Of the 12 patients with a vaginal erosion, 10 expressed symptoms in relation with their erosion. After partial resection, eight patients (80% of patients with symptomatic erosion) did not have more complain. Of these, 50% were continent, the other with mostly a slight recurrence accessible to a second suburethral sling. First endoscopic section was a minimally invasive option for bladder erosion. However, an only cystoscopic approach seemed to be not sufficient to cut the sling as far as possible. After section, two patients have been treated from a laparotomy with bladder dissection, one for immediate outcome unsatisfactory, the other for reccurent symptoms. The results for continence were excellent as the suburethral portion was not resected., Conclusion: Our study showed the importance of regular clinical surveillance, feasibility and the relative success of this conservative approach. The technical feasability and the increasing number of patients must not forget to respect good indication and rigorous technique. These complications invite us to moderate our indications especially for young patients.

Imaging: INDICATIONS FOR IMAGING: Apart from ultrasound assessment of post-voiding residual urine, radiological examinations are not recommended for the initial work-up of non-neurological female urinary incontinence. CYSTOGRAPHY: Cystography is not recommended as a first-line examination to evaluate uncomplicated stress, urge or mixed urinary incontinence. Cystography may be recommended in the case of complex, complicated or relapsing urinary incontinence, discordance between clinical findings and urodynamic assessment or in the presence of associated prolapse, in which case colpocystodefecography or even dynamic MRI should be preferred. URINARY TRACT ULTRASOUND: Ultrasound is not recommended for the initial work-up of pure stress urinary incontinence or genital prolapse Ultrasound without forced diuresis and after a spontaneous void, is recommended for the assessment of post-voiding residual urine and to assess complicated suburethral tape. Ultrasound is an optional examination in the case of complex or relapsing urinary incontinence, discordance between clinical findings and urodynamic assessment or in the presence of prolapse. PELVIC MRI: Dynamic MRI is not currently recommended for the initial work-up of urinary incontinence.

Introduction: Following the notification of forty cases of varying degrees of vision loss in patients using phosphodiesterase-5 (PDE-5) inhibitors, the FDA (Food and Drug Administration) examined the possible link between these treatments of erectile dysfunction and NOIAN (nonarteritic anterior ischemic optic neuropathy). Following this investigation, the FDA requested modification of the summary of product characteristics (SPC) for this therapeutic category. The authors review this problem, especially in France., Method: The authors performed a search of the Pubmed database and the French Pharmacovigilance database., Results: Since September 2006, 11 publications concerning 19 cases (14 with sildenafil and 2 with tadalafil) have been published. The mean age of these patients was 59.5 years (range: 42 to 69). Doses varied from 50 to 100 mg for sildenafil and 20 mg for tadalafil. Adverse effects (loss of visual acuity and decreased visual field) occurred between 30 min and 36 h after oral dosing. In 5 cases, treatment had been taken for more than one year. Ocular fundus examination showed papilloedema associated with several haemorrhages. Three patients presented a positive challenge. Several patients had a known risk factor for the development of NOIAN. One case was also reported to French Pharmacovigilance., Discussion: The population with erectile dysfunction also often presents generalized endothelial disease, which also constitutes a risk factor for NOIAN. Although no cases of NOIAN were reported during the initial clinical trials, the rapid onset of NOIAN after the dose of PDE-5 inhibitor and several cases of positive challenge suggest a possible causal relationship with these drugs. The ocular action of PDE-5 inhibitors could be explained by a modification of retinal blood flow related to their pharmacological effects., Conclusion: The link between PDE-5 inhibitors and NOIAN has not been formally established. Before new studies are conducted to clarify this situation, practitioners must be aware of the potential ocular adverse effects related to the dose of PDE-5 inhibitors so that they can inform patients and notify any new cases. The SPCs of PDE-5 inhibitors were modified at the request of the FDA on 8 July 2005.

Objective: To prospectively evaluate the quality of life of cancer patients at the palliative stage after implantation of an extra-anatomical ureteric prosthesis as an alternative to permanent percutaneous nephrostomy (PCN)., Material and Methods: A series of 27 prostheses in 19 patients with PCN was prospectively evaluated. The ureteric prosthesis (Detour) consists of two concentric tubes glued to each other. The inner tube is made of silicone and the outer tube is made of polyester. This prosthesis is introduced percutaneously into the renal pelvis as an alternative to nephrostomy. It is tunnelled subcutaneously and is introduced into the bladder via a short incision. Patients were reviewed every three months for 18 months or until death. The EORTC QLQ-C30 self-administered questionnaire was used to evaluate the patients' quality of life. The functioning and position of the prostheses were verified by ultrasound and/or intravenous urography (IVU)., Results: There were no failures of prosthesis placement and no intraoperative or early postoperative complications. Injection of the suprapubic incision was observed in 3 cases, in patients with pre-existing bladder disease (radiation cystitis or bladder tumour). The mean follow-up was 7.8 months: 6.6 months for the group of patients who died (15) and 12 months for the 4 patients still alive at the end of the study. Functional scores improved due to elimination of the external nephrostomy tube. In parallel, physical score deteriorated due to disease progression. Overall quality of life and index of satisfaction were improved by elimination of the external diversion., Conclusion: Subcutaneous pyelovesical diversion ensures a better quality of life than classical percutaneous nephrostomy in cancer patients at the palliative stage.

Introduction and Objectives: Practice on a Pelvitrainer training is an essential part of the training of surgeons in laparoscopy. Most university departments are equipped with this type of model, but this equipment is expensive, cumbersome and often poorly accessible. The authors propose a new laparoscopy home training model and compare its performances with those of the reference training model., Material and Method: The laparoscopy home training model is composed of a laptop computer; a Web Cam and a translucent plastic box. Ten operators with various levels of training were timed during 4 simple exercises performed on the home training model and were then timed when performing 6 interrupted sutures with this model and with a Pelvitrainer, Results: All operators successfully performed the proposed exercises. The mean operating time was correlated with the level of training (35 minutes versus 15 minutes for the 3 most experienced operators). The suture time was comparable with the home trainer (14 minutes) and the Pelvitrainer (13 minutes). The home training model is less expensive (75 euros), more accessible and easier to install (3 minutes) than the Pelvitrainer and can be used outside of medicalized structures., Conclusion: Trainee operators can practice laparoscopy at home. The manufacture of a Home-trainer requires simple material. The training capacities of this model are similar to those of a Pelvitrainer, but it is less cumbersome, less expensive and more readily available. This type of model could be used by each operator at home to improve his/her performances and to accelerate training.

Objective: Benign prostatic hyperplasia (BPH) is a disease affecting about 25% of men over the age of 40. One half of these men report symptoms that interfere with their daily activities., Material and Methods: In this multicentre study, 102 patients with BPH were treated by transurethral needle ablation (TUNA). The efficacy of treatment was evaluated for 12 months after the operation by means of Madsen and IPSS (International Prostate Symptom Score) scores. The course of uroflowmetry and quality of life (International Score) and sexual function were also assessed for one year. The safety of treatment was evaluated according to the type and frequency of complications. The results show an immediate and significant improvement of symptoms (p < 0.0001 for Madsen and IPSS scores and maximum flow rate between M0 and M12) demonstrating the efficacy of the TUNA system. A very positive impact of TUNA was demonstrated on quality of life. No negative impact was reported on sexual function and the operation had very few repercussions with a low adverse event rate. The retreatment rate (surgical and/or drug) was evaluated 36 months after the operation by means of an optional follow-up questionnaire subsequently completed by the investigators., Results: After 3 years, based on the 80 questionnaires returned, 43 patients (53.8%) were stable and did not need any other medical or surgical treatment for BPH. Thirty-seven (37) patients (46.3%) required retreatment: 21 were treated with drugs (26%), 17 were treated surgically (21.25%) including 1 patient who was also retreated with drugs. This study demonstrates the significant and lasting improvement of BPH symptoms by TUNA, which constitutes an alternative attractive to surgery in young patients and/or patients worried about their sexuality.

Introduction: Laparoscopic adrenalectomy is the reference technique for the treatment of adrenal tumours. This retrospective study reports the experience of 100 consecutive laparoscopic adrenalectomies, in order to assess its indications, the incision, the morbidity and to determine the limitations of this procedure., Material and Methods: Between April 1994 and June 2004, 100 laparoscopic adrenalectomies were performed in 92 patients via a transperitoneal (n = 93) or retroperitoneal (n = 7) approach, with 84 unilateral and 8 bilateral adrenalectomies. The mean age was 52 years. The operative and postoperative characteristics and the functional results were evaluated., Results: The mean operating time was 112 min [70-175] via the retroperitoneal approach, 101 min [40-215] via the transperitoneal approach, and 135 min [120-270] for bilateral adrenalectomies. The mean tumour diameter was 44 mm [10-120 mm]. The mean blood loss was 215 ml [0-1210 ml]. Ten patients were transfused. The mean hospital stay was 3 days. Histology revealed 25 Conn adenomas, 20 cortisol-secreting adenomas and Cushing syndrome, 22 phaeochromocytomas, 20 metastases, 2 adrenal cortical adenomas, and 11 incidentalomas. Conversion to "open" surgery were necessary for technical difficulties in 6% of cases. There were 7 minor postoperative complications (7%) and 4 late complications (4%) (deep vein thrombosis, effusion, 2 local recurrences). Four patients in the group with secondary adrenal tumours were alive without recurrence 18, 20, 44 and 48 months after adrenalectomy. Antihypertensive treatment was stopped in 16 of the 25 patients operated for Conn adenoma. The mean follow-up was 31 months [5-98 months]., Conclusion: This technique has a low morbidity, requires minimal postoperative analgesia and a short hospitalisation. The retroperitoneal or transperitoneal approach must be chosen as a function of the patient's history and the surgeon's habits. Tumours larger than 8 cm can be resected, but with a higher morbidity. Laparoscopic adrenalectomy for malignant tumours is associated with higher morbidity.

Objective: To evaluate the efficacy and morbidity of laparoscopic surgery in the management of upper urinary tract stones., Material and Method: Between January 1998 and July 2004, 18 patients (14 males, 4 females) underwent laparoscopic extraction of an upper urinary tract stone. Stones were lumbar (n=13), ureteropelvic (n=2), iliac (n=1), inferior caliceal (n=1), and intradiverticular (n=1) with a mean diameter of 15 mm (range: 8-25 mm). Fifteen stones were obstructive. Laparoscopy was performed after failure of one or several previous treatments in 9 cases: ESWL (n=2), retrograde (n=1), anterograde ureteroscopy (n=6). A retroperitoneal approach (n=15) was used for caliceal and lumbar stones and a transperitoneal approach (n=3) was used for pyeloureteric and iliac stones., Results: The mean operating time was 80 minutes (range: 40-150 min). The mean blood loss was 50 cc (range: 0-250 cc). The mean length of stay was 3.86 days (range: 2 to 7 days). Fifteen patients were drained by a double J stent for one month. The stone was removed by laparoscopy in every case. One patient developed a urinoma requiring surgical repair via a lumbar incision., Conclusion: Laparoscopy currently constitutes an attractive alternative for the treatment of upper urinary tract stones and, in this study, was indicated for first-line treatment of obstructive stones larger than 12 mm impacted in the ureter or after failure of previous treatments.

Objective: Urinary stones, affecting 10% of the French population, is a frequent disease. Data of the literature on this disease in subjects over the age of 60 years reveal age-related changes of risk factors, especially affecting urine composition, but very few data have been reported concerning the clinical characteristics of the disease. Due to the absence of recent data on urinary stones in subjects over the age of 60 in France, we decided to study the epidemiology and urological treatment of urinary stones in the elderly in France., Material and Method: From November 2001 to August 2002, a survey concerning urinary stones in subjects over the age of 60 was performed by the Association Française d'Urologie Stone Committee among urologist members of the AFU. The parameters studied were epidemiological, clinical, metabolic and therapeutic. The results were analysed on the overall patient population and on the subgroup of patients over the age of 70., Results: The study included 176 patients over the age of 60, 110 of whom were over the age of 70. These patients presented their first episode of urinary stones in 41% of cases. Renal colic was the most frequent presenting symptom. Signs of severity were frequently associated, with urinary tract infection in 24% of cases, associated with sepsis in 49% of cases after the age of 70 years. The incidence of uric acid stones was higher than in the general population., Conclusion: Urinary stones can often occur for the first time after the age of 60. This disease appears to be more serious than in the general population due to the high incidence of infectious complications. Uric stones also appear to be more frequent. A multidisciplinary study based on a larger population is necessary to confirm these results.

The authors report the case of a 25-year-old woman with a history of acute lymphoblastic leukaemia in complete remission after being treated, three years previously, by chemotherapy, radiotherapy and allogeneic bone marrow transplantation, who was admitted to the urology department following an episode of haematuria with severe anaemia. This clinical case report illustrates the diagnostic and therapeutic approach adopted in relation to the severity of the haematuria, in which haemostatic surgery was only considered as a last resort.

Objectives: To evaluate the haemorrhagic complications of PCNL, to analyse their management and to identify predisposing factors., Material and Methods: Out of a series of 772 cases of PCNL, 18 patients developed severe haemorrhage requiring a haemostatis procedure (2.3%): 13 males and 5 females with a mean age of 57 years (38-79), and one case on a solitary kidney. The mean time to onset of haemorrhage was 18 days (--48 days)., Results: Three nephrectomies for haemostatis were performed at the beginning of our experience. Renal arteriography was performed in 15 patients and was abnormal in 13 patients, showing 3 arteriovenous fistulas, 8 false aneurysms, 3 arteriolar injuries. All these vascular abnormalities were successfully treated by highly selective embolization. In 2 cases, arteriography was normal with a spontaneously favourable course. Comparison of the 2 groups of PCNL, with haemorrhage versus without haemorrhage, failed to demonstrate any risk factors., Conclusion: Severe haemorrhage following PCNL is a rare complication, but impossible to predict. Selective embolization allows control of bleeding and currently constitutes the treatment of choice.

By taking into account the properties of this stent, which must eventually become completely epithelialized, it is important to clearly define its length so that its proximal and distal ends lie in healthy mucosa and the stricture must be dilated to allow maximum expansion of the stent. On the other hand, due to the severity of periurethral fibrosis, which can advance through the stent, this solution is contraindicated in the case of posttraumatic stricture or recurrence after urethroplasty. Apart from these contraindications, this is a rapid, sophisticated and effective procedure for which the current data of the literature are convincing.

The development of laparoscopy in the field of urology has been considerable since 1991. In order to evaluate the use of this technique in the French urology community and the need to develop evaluating and teaching structures for this technique, a postal questionnaire was sent to 714 members of the Association Française d'Urologie (AFU) on June 23, 1993. The reply rate was 22% and 72 of the responders (46%) performed urological laparoscopy. A total of 684 laparoscopic urological procedures were reported, corresponding to an average of 9.5 procedures per operator. 45 operators had performed fewer than 16 laparoscopic procedures. The complication rate was 5% with a perioperative mortality of 0.3%. These figures should be considered to be minimal values. Eighty six responders (54%) did not perform laparoscopy. Forty seven of them (57%) were waiting for these techniques to demonstrate their practical value. Eighty two urologists thought that laparoscopic lymph node dissection had a role to play in the diagnostic and therapeutic strategy of prostatic cancer. One hundred and thirteen urologists (85%) considered that the development of urological laparoscopy would be moderate. Eighty nine urologists answer the question concerning possible training in these techniques and 77 of them intended to learn laparoscopic techniques.(ABSTRACT TRUNCATED AT 250 WORDS)

The authors present a retrospective analysis of 30 cases of renal cancer with vena cava thrombus with a sufficient follow-up to allow analysis of the long-term prognosis. Only three patients are still alive with a follow-up of 12, 34 and 57 months. The actuarial survival for the overall population was 55%, 37% and 22% at 1, 2 and 3 years respectively. Three essential factors influenced the prognosis of these patients: the presence of distant metastases, lymph node invasion and the highest cephalic level of extension of the thrombus. Renal cancer with vena cava thrombus without metastases and without lymph node involvement has a good prognosis (100% 2-year survival), but is very rare (4 out of 30 cases), so that renal cancer with vena cava thrombus must be considered to be a serious disease (3 survivors out of 30).

The authors report 3 cases of ilio-ureteric fistulae following aorto-iliac reconstructive surgery. They also review 6 similar cases published in the worldwide literature. All of these cases have in common the appearance of a uretero-arterial fistula several years after the vascular operation on the iliac artery. The postoperative course of iliac thromboendarterectomy appears to be principally responsible, as in the 3 cases presented here, resulting in a pseudoaneurysm over the arteriotomy closure, especially as a patch angioplasty had been performed. This complication is exceptional. The diagnosis must be suspected in the case of profuse haematuria and a suggestive history and should be confirmed, when possible, by intravenous urography, retrograde ureteropyelography, arteriography, or even computed tomography. Treatment is complex and consists of a vascular and urological procedure depending on the degree of urgency and the possibilities of reconstruction.

17 patients with upper urinary tract tumours were investigated by endoscopy. 3 patients (Group I) with fibrous or fibroepithelial polyps were treated via a retrograde approach and did not develop any recurrences. 2 patients (Group II) developed unexplained haematuria: the diagnosis of high-grade carcinoma was confirmed by endoscopy and they were treated by nephroureterectomy. 12 patients (Group III) with low grade non-invasive urothelial carcinoma, in whom radical surgical was not indicated, were treated conservatively via the percutaneous (13 tumours) or retrograde (1 tumour) endoscopic approach. The local recurrence rate was 33% (4 out of 12 tumours) for a mean follow-up of 22 months. The recurrences were treated by repeated endoscopy in 3 patients, and by nephroureterectomy in 1 patient. Endoscopic treatment of upper urinary tract tumours should be reserved for benign tumours and selected cases of low-grade, non-invasive urothelial carcinoma.